معرفی
Chil-Yong Kang is a Professor of Virology in the Department of Microbiology and Immunology at the Schulich School of Medicine and Dentistry, University of Western Ontario, Canada. He is a molecular virologist with a distinguished career spanning academia and leadership roles, including Chairmanship of Microbiology and Immunology at the University of Ottawa and Dean of Science at Western Ontario (1992–1999).
- PhD in Virology from McMaster University (1971).
- Postdoctoral training at the University of Wisconsin-Madison (1971–1974) under Nobel Laureate Howard Temin.
- Doctor of Science (D.Sc.) from McMaster University and Carleton University.
Dr. Kang’s research focuses on developing antiviral vaccines and therapeutic agents for diseases such as hepatitis C, Ebola, MERS, Zika virus microcephaly, and HIV/AIDS. Notable achievements include the SAV001 HIV vaccine (completed Phase I trials) and a replication-competent SARS-CoV-2 vaccine platform. He has authored 148 peer-reviewed papers and holds 15 international biotechnology patents covering over 70 countries.
Scientific awards and honors include:
- Korean-Canadian Heritage Award (1989)
- Ho-Am Prize in Medicine (1999)
- Order of Innovation from the Republic of Korea (2002)
- Queen Elizabeth II Diamond Jubilee Medal (2012)
- Life-time Fellow of the Royal Society of Canada (1993)
He has served on grant selection committees for Canadian and U.S. federal agencies, participated in the Science Technology Innovation Council (STIC) of Canada, and reviewed for journals including Journal of Virology and Journal of Biological Chemistry. Dr. Kang leads the Kang Lab, contributing to vaccine innovation and molecular virology research.
